The diabetic nephropathy market is driven by the growing burden of diabetes and the increasing demand for effective treatments for kidney disease. Advances in therapeutics, including new drug classes ...

Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and ...

These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois. The presentation will focus on Emi-Le’s ...

we are presenting more updated follow-up data and combination therapy results of IBI363 at the ASCO Congress this year. From a comprehensive body of clinical evidence that includes ORR ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data ...

“There are no additional approved therapies in this setting. Libtayo is the first and only immunotherapy to demonstrate a clinical benefit compared to standard of care surgery and radiation alone. The ...

Research highlights include: Oral Presentation ... from 1:30 PM–4:30 PM CDT Overview: LLMs show promise for improving abstraction efficiency, converting clinical data from unstructured EHRs ...

“The San Jacinto program has always been an NCRA favorite, being the first NCRA-accredited [clinical data management] program,” Mary Maul, NCRA manager of education programs, said in the news ...

AbbVie Inc ABBV stock is trending on Tuesday after the U.S. drug giant announced that key data from ... Society of Clinical Oncology (ASCO) Annual Meeting. An oral presentation on investigational ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that new data from several studies of ...